Single-use bioprocessing connectors market set to nearly double by 2030

The global single-use bioprocessing connectors market is projected to grow from $1.65 billion in 2025 to $3.92 billion by 2030, according to a new report from The Business Research Company. Demand for biosimilars, sterile fluid transfer and broader adoption of single-use technologies are driving the expansion, with North America leading today and Asia-Pacific expected to grow fastest.

Why it matters: - Single-use bioprocessing connectors are becoming a core part of sterile drug manufacturing as biopharma companies push to reduce contamination risk and improve process efficiency. - The market’s projected jump to $3.92 billion by 2030 signals continued investment in single-use systems, especially in biologics, cell therapies and contract manufacturing.

What happened: - The Business Research Company published its "Single-Use Bioprocessing Connectors Market Report 2026" on Aug. 26, 2026. - The report says the market will rise from $1.65 billion in 2025 to $1.96 billion in 2026. - The report forecasts a 18.8% CAGR from 2025 to 2026 and an 18.9% CAGR through 2030. - The company expects the market to reach $3.92 billion by 2030. - North America held the largest market share in 2025. - Asia-Pacific is projected to be the fastest-growing region during the forecast period.

The details: - Single-use bioprocessing connectors are disposable devices that link tubing, bags, filters and bioreactors in bioprocessing systems. - The connectors support sterile, leak-proof fluid transfer in media preparation, fermentation and purification. - The devices eliminate cleaning and sterilizing between batches. - The report links recent growth to demand for sterile connectors, expansion in biopharmaceutical manufacturing, limited upstream automation, reliance on traditional connectors and strict regulatory requirements. - Future growth is tied to broader adoption of single-use technologies, aseptic connectors in automated workflows, more contract manufacturing, advances in biologics and cell therapies, and lower cross-contamination risk. - The report points to trends including disposable bioprocess systems, sterile fluid transfer, more upstream automation, single-use fill-finish operations and standardized connector interfaces. - Single-use connectors help biosimilar manufacturers maintain product quality, reduce batch-failure risk and lower operating costs. - Cardinal Health said in January 2023 there were 33 FDA-approved biosimilars as of January 2022, with 21 commercially available. - Cardinal Health said the total rose to 40 approvals in 2023, with 25 biosimilars on the market. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspot infographics, key technology analysis and updated graphics and tables. - The report offers a free sample at Download a free sample. - The full report is available at View the full market report.

Between the lines: - The forecast suggests bioprocessing buyers are prioritizing flexible, contamination-resistant systems over reusable setups. - The focus on automation and standardized interfaces points to a market moving from niche component demand toward more integrated manufacturing workflows. - Rising biosimilar approvals indicate a larger pool of therapies that may rely on single-use infrastructure.

What's next: - The report expects the fastest growth to come from Asia-Pacific as biomanufacturing capacity expands there. - Additional adoption should follow as more drug makers and contract manufacturers move to single-use and aseptic processing platforms. - The Business Research Company says its 2026 research package will continue adding dashboards, scoring tools and trend analysis for market planning.

The bottom line: - Single-use bioprocessing connectors are moving from a support product to a growth market shaped by biosimilars, automation and the push for cleaner, faster biomanufacturing.